GGrantIndex
← Search

Immunophenotyping Shared Resource

$201,991P30FY2024CANIH

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

CORE 010 – IMMUNOPHENOTYPING SHARED RESOURCE SUMMARY/ABSTRACT The mission of the Immunophenotyping Shared Resource (IPSR) is to advance immuno-oncological translational research projects by providing a rigorous platform to assess the immunological impact of anti-cancer therapy and deepen mechanistic understanding of cancer immunology. During the current project period there has been an explosion in our knowledge of host-tumor interactions and the mechanisms by which cancer cells evade host immune-surveillance. Fully a third of the clinical trials underway at the Vanderbilt-Ingram Cancer Center (VICC) include an immuno-oncology component. Immune tumor infiltrates, the immuno- microenvironment, and the patient immune state are rapidly becoming standard biomarkers for patient selection, yet most clinical investigators do not have wet laboratory capabilities to define the immunophenotype of the tumor or the host. As a result, there is a critical need for a centralized Shared Resource to coordinate and perform comprehensive analysis of the immune cell repertoire and state (“immunophenotyping”) from clinical trial and preclinical biospecimens. To meet this need, we developed a highly integrated platform to drive and manage comprehensive immunophenotyping by adding capabilities to the former Antibody Production Shared Resource (APSR), thus enabling deep immune analysis in the newly evolved IPSR. High-quality antibodies are necessary for immunophenotyping, so this transition leverages the existing expertise in multiple antibody technologies while broadening the scope of work to include immunophenotyping. The immune analyses will be conducted in collaboration with several existing VICC Shared Resources including the Flow Cytometry Shared Resource (FCSR) for analysis of peripheral blood and bone marrow samples and/or dissociated tumor samples; the Translational Pathology Shared Resource (TPSR) for multi-immunofluorescence analysis of solid tumor samples; and the Genomic Sciences Shared Resource (GSSR) for deep sequencing of neoepitopes and single cell RNAseq analysis. The IPSR staff work closely with clinical, basic and population sciences investigators to design experimental approach, and to rigorously interpret resulting data, thus providing these investigators a “one stop shop” for coordinating immunophenotyping. The IPSR is co-led by three established faculty members with a wealth of experience in performing highly complex immunological assays. Collectively, their extensive knowledge in immunologic assays, immuno-oncology, single cell biology, genomics, host-tumor interactions, and use of clinically derived biospecimens makes their expertise critical to the success of the Shared Resource. During the current project period IPSR collaborations included 274 laboratory projects with 161 unique investigators across seven VICC Research Programs that have been recognized by 40 publications.

View original record on NIH RePORTER →